Acquired hyperfibrinolysis as the presenting sign of metastatic breast cancer: A case report

Lu,Guanyu; Jia,Lin; Yang,Ruohan; Lv,Zheng; Cui,Jiuwei

doi:10.3892/ol.2023.13692

Acquired hyperfibrinolysis as the presenting sign of metastatic breast cancer: A case report

Authors:
- Guanyu Lu
- Lin Jia
- Ruohan Yang
- Zheng Lv
- Jiuwei Cui
View Affiliations

Affiliations: Cancer Center, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: February 2, 2023 https://doi.org/10.3892/ol.2023.13692
Article Number: 106

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Abstract. Fibrinolysis is a bleeding disorder characterized by hypofibrinogenemia caused by abnormal activation of fibrinolytic system function. Patients with cancer are prone to hypercoagulable and should be vigilant for the risk of venous thrombosis. However, patients with tumors in which bleeding is the first manifestation are relatively rare. The present study reports the case of a 52‑year‑old woman with metastatic breast cancer with acquired hyperfibrinolysis as the first manifestation. Hyperfibrinolysis is an important sign and manifestation of disease progression. In this case, fibrinogen was used as a sensitive biomarker of tumor burden to specifically predict the efficacy of the antitumor therapy. Effective antitumor therapy can improve the hyperfibrinolysis of patients, and so the fibrinogen levels gradually increased. In conclusion, the present case showed acquired hyperfibrinolysis with bleeding symptoms, which is an uncommon paraneoplastic phenomenon in breast cancer, especially when combined with bone marrow metastasis, as in the present case. Timely diagnosis and treatment of the primary disease is the fundamental way to improve hyperfibrinolysis. As an effective biomarker, fibrinogen level predicts the changes in a patient's illness and guides the clinical diagnosis and treatment process.

View Figures

View References

1	Kolev K and Longstaff C: Bleeding related to disturbed fibrinolysis. Br J Haematol. 175:12–23. 2016. View Article : Google Scholar : PubMed/NCBI
2	Longstaff C and Kolev K: Basic mechanisms and regulation of fibrinolysis. J Thromb Haemost. 13 (Suppl 1):S98–S105. 2015. View Article : Google Scholar : PubMed/NCBI
3	Rijken DC and Lijnen HR: New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost. 7:4–13. 2009. View Article : Google Scholar : PubMed/NCBI
4	Lin H, Xu L, Yu S, Hong W, Huang M and Xu P: Therapeutics targeting the fibrinolytic system. Exp Mol Med. 52:367–379. 2020. View Article : Google Scholar : PubMed/NCBI
5	Chapin JC and Hajjar KA: Fibrinolysis and the control of blood coagulation. Blood Rev. 29:17–24. 2015. View Article : Google Scholar : PubMed/NCBI
6	Franchini M and Mannucci PM: Primary hyperfibrinolysis: Facts and fancies. Thromb Res. 166:71–75. 2018. View Article : Google Scholar : PubMed/NCBI
7	Rein-Smith CM and Church FC: Emerging pathophysiological roles for fibrinolysis. Curr Opin Hematol. 21:438–444. 2014. View Article : Google Scholar : PubMed/NCBI
8	Leebeek FW and Rijken DC: The fibrinolytic status in liver diseases. Semin Thromb Hemost. 41:474–480. 2015. View Article : Google Scholar : PubMed/NCBI
9	Rabizadeh E, Cherny I, Lederfein D, Sherman S, Binkovsky N, Rosenblat Y and Inbal A: The cell-membrane prothrombinase, fibrinogen-like protein 2, promotes angiogenesis and tumor development. Thromb Res. 136:118–124. 2015. View Article : Google Scholar : PubMed/NCBI
10	Vanel D: The American college of radiology (ACR) breast imaging and reporting data system (BI-RADS): A step towards a universal radiological language? Eur J Radiol. 61:1832007. View Article : Google Scholar : PubMed/NCBI
11	Plichta JK, Ren Y, Thomas SM, Greenup RA, Fayanju OM, Rosenberger LH, Hyslop T and Hwang ES: Implications for breast cancer restaging based on the 8th edition AJCC staging manual. Ann Surg. 271:169–176. 2020. View Article : Google Scholar : PubMed/NCBI
12	National Institutes of Health, National Cancer Institute, U.S. Department of Health and Human Services, . Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5×11.pdfPublished November 27, 2017. June 20–2020
13	Pelosof LC and Gerber DE: Paraneoplastic syndromes: An approach to diagnosis and treatment. Mayo Clin Proc. 85:838–854. 2010. View Article : Google Scholar : PubMed/NCBI
14	Soomro Z, Youssef M, Yust-Katz S, Jalali A, Patel AJ and Mandel J: Paraneoplastic syndromes in small cell lung cancer. J Thorac Dis. 12:6253–6263. 2020. View Article : Google Scholar : PubMed/NCBI
15	Franchini M, Zaffanello M and Mannucci PM: Bleeding disorders in primary fibrinolysis. Int J Mol Sci. 22:70272021. View Article : Google Scholar : PubMed/NCBI
16	Hunt BJ: Bleeding and coagulopathies in critical care. N Engl J Med. 370:21532014. View Article : Google Scholar : PubMed/NCBI
17	Naina HVK, Patnaik MM, Ali UA, Chen D and Ashrani AA: Systemic fibrinolysis caused by tissue plasminogen activator-producing metastatic breast cancer. J Clin Oncol. 28:e167–e168. 2010. View Article : Google Scholar : PubMed/NCBI
18	Winther-Larsen A, Sandfeld-Paulsen B and Hvas AM: Hyperfibrinolysis in patients with solid malignant neoplasms: A systematic review. Semin Thromb Hemost. 47:581–588. 2021. View Article : Google Scholar : PubMed/NCBI
19	Kwaan HC and Lindholm PF: Fibrin and fibrinolysis in cancer. Semin Thromb Hemost. 45:413–422. 2019. View Article : Google Scholar : PubMed/NCBI
20	Cesarman-Maus G and Hajjar KA: Molecular mechanisms of fibrinolysis. Br J Haematol. 129:307–321. 2005. View Article : Google Scholar : PubMed/NCBI
21	Sacco E, Pinto F, Sasso F, Racioppi M, Gulino G, Volpe A and Bassi P: Paraneoplastic syndromes in patients with urological malignancies. Urol Int. 83:1–11. 2009. View Article : Google Scholar : PubMed/NCBI
22	Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, et al: Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 94:116–128. 2002. View Article : Google Scholar : PubMed/NCBI
23	Ruszkowska-Ciastek B, Kwiatkowska K, Bielawska S, Robakowska M, Bielawski K and Rhone P: Evaluation of the prognostic value of fibrinolytic elements in invasive breast carcinoma patients. Neoplasma. 67:1146–1156. 2020. View Article : Google Scholar : PubMed/NCBI
24	Wrzeszcz K, Słomka A, Zarychta E, Rhone P and Ruszkowska-Ciastek B: Tissue plasminogen activator as a possible indicator of breast cancer relapse: A preliminary, prospective study. J Clin Med. 11:23982022. View Article : Google Scholar : PubMed/NCBI
25	Kulić A, Cvetković Z and Libek V: Primary hyperfibrinolysis as the presenting sign of prostate cancer: A case report. Vojnosanit Pregl. 73:877–880. 2016. View Article : Google Scholar : PubMed/NCBI
26	Stephens RW, Brünner N, Jänicke F and Schmitt M: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat. 52:99–111. 1998. View Article : Google Scholar : PubMed/NCBI
27	Duffy MJ, McGowan PM, Harbeck N, Thomssen C and Schmitt M: uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res. 16:4282014. View Article : Google Scholar : PubMed/NCBI
28	Malmström P, Bendahl PO, Boiesen P, Brünner N, Idvall I and Fernö M; South Sweden Breast Cancer Group, : S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than nottingham prognostic index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol. 19:2010–2019. 2001. View Article : Google Scholar : PubMed/NCBI
29	Duffy MJ: The urokinase plasminogen activator system: Role in malignancy. Curr Pharm Des. 10:39–49. 2004. View Article : Google Scholar : PubMed/NCBI
30	Kyyriäinen J, Bolkvadze T, Koivisto H, Lipponen A, Pérez LO, Ekolle Ndode-Ekane X, Tanila H and Pitkänen A: Deficiency of urokinase-type plasminogen activator and its receptor affects social behavior and increases seizure susceptibility. Epilepsy Res. 151:67–74. 2019. View Article : Google Scholar : PubMed/NCBI
31	Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M and Blasi F: The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA. 99:1359–1364. 2002. View Article : Google Scholar : PubMed/NCBI
32	Kortlever RM, Higgins PJ and Bernards R: Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol. 8:877–884. 2006. View Article : Google Scholar : PubMed/NCBI
33	Kopp HG, Krauss K, Fehm T, Staebler A, Zahm J, Vogel W, Kanz L and Mayer F: Symptomatic bone marrow involvement in breast cancer-clinical presentation, treatment, and prognosis: A single institution review of 22 cases. Anticancer Res. 31:4025–4030. 2011.PubMed/NCBI
34	Garufi G, Carbognin L, Orlandi A, Palazzo A, Tortora G and Bria E: The therapeutic challenge of disseminated bone marrow metastasis from HR-positive HER2-negative breast cancer: Case report and review of the literature. Front Oncol. 11:6517232021. View Article : Google Scholar : PubMed/NCBI
35	Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, et al: Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 18:452–478. 2020. View Article : Google Scholar : PubMed/NCBI